short selling action, page-7

give it a couple of months before they release the data.

someone correct me if i am wrong, but in europe and australia, pharmaxis will only need to apply for modifications to labelling, rather than the full-on application for approval, is that correct?

if so, the time between applying and finding out the result of the application should be a much speedier process

i think it is a tad oversold at the moment. they have products approved, and while bronchitol missed out on FDA approval, it is currently approved in Europe and Australia, with sales only set to increase. Furthermore, it is the same process of receiving a rejection, followed by negotiations and finally approval for adults only.

anyway, i'm not sure how much negotating they get to do between the initial decision and march 18, they may need to re-apply, but i can't see the price going lower than this, except for maybe a nervous sell off if march 18 confirms a rejection.